NanaBis
Phase 2- Indications
- Cancer pain
Company intelligence / Profile preview
Medlab Clinical
Botany, NSW, Australiamedlab.co ↗
- Ownership
- Private
- Employees
- ~42
- Development stage
- Phase 2
01
Overview
NanaBis™, a cannabinoid-based medicine delivered via NanoCelle®, has shown significant reduction in cancer bone pain with improvements in quality of life and reduced opioid use. Compassionate use data supports efficacy claims; regulatory submissions are being prepared for US FDA review using the abbreviated pathway.
- Therapeutic areas
- PsychiatryMetabolic DisordersNephrologyRheumatologyEndocrinologyImmunologyOncologyNeurology
- Modalities
- Small moleculeNanoparticle delivery therapyLive biotherapeutic product therapyNutraceuticals
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on Medlab Clinical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Medlab Clinical.